FFF Enterprises   Report issue

Contributed to NME For profit Phase 3
Founded: Temecula CA United States (1988)
Status: Left NME R&D (2016)

Organization Overview

First Clinical Trial
2006
NCT00338442
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2006

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

immune globulin (human) (Gamastan) (1 trial)

Drugs in Other Trials (1)

varicella zoster immune globulin (human) (varizig) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Immunologic Deficiency Syndromes (Phase 3)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2